Compare Nasdaq100 ETF (QQQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Nasdaq100 ETFTrade

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Nasdaq100 ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Nasdaq100 ETF trades at $715.4, while State Street SPDR S&P Biotech ETF trades at $159.85. Which is the better fit depends on your goals.

	QQQ	XBI
52-Week High	$746.16	$169.55
52-Week Low	$558.34	$93.43
Sector	—	Broad Market / Factor

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nasdaq100 ETF

QQQ trades at $718.36, showing minimal daily movement with a slight decline of 0.08%. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF maintains its position as a leading Nasdaq-100 tracker, though financial ratios are not applicable for this index fund structure. Recent news highlights ongoing institutional interest and comparisons with competing funds.

The outlook remains positive given the bullish technical setup and strong institutional backing. However, investors face risks from market volatility and fee structure comparisons with competing funds. The divided analyst consensus reflects uncertainty about near-term performance despite the fund's long-term growth trajectory.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

QQQ

TQQQ returned 59.18% vs. QQQ's 24.99%, but leverage costs and daily resets reduce its triple return over time.24/7 Wall Street · 15 hours agoNeutral iShares Future AI & Tech ETF gains 78.2% in 12 months but carries high risk due to sector concentration and weak holdings.Seeking Alpha · 20 hours agoNeutral Michael Burry makes Lululemon his largest portfolio bet amid market volatility.Finbold · 1 day agoBearish View details →

XBI

Biotech ETF IBB outperformed S&P 500 by 22 points in 3 months amid pharma patent cliff deals.24/7 Wall Street · 2 days agoBullish State Street SPDR S&P Biotech ETF (XBI) rated Buy with 8%-14% returns expected despite prior 76% rallySeeking Alpha · 4 days agoBullish View details →

About Nasdaq100 ETF

The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.